Tech Company Financing Transactions
ALP Bio Funding Round
On 7/3/2026, ALP Bio received $185 thousand in investment from Venture Kick.
Transaction Overview
Company Name
Announced On
7/3/2026
Transaction Type
Venture Equity
Amount
$185,000
Round
Undisclosed
Investors
Proceeds Purpose
The Venture Kick funding will support ALP Bio's first pilot projects with pharmaceutical partners.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Zürcherstrasse 39d
Schlieren, 8952
Switzerland
Schlieren, 8952
Switzerland
Phone
Undisclosed
Website
Email Address
Overview
Alp Bio's platform combines tonsil organoid technology and state-of-the-art protein AI to assess and reduce immunogenic risk in therapeutic antibodies before they can impact patient outcomes. ALP Bio reduces immunogenicity risk by integrating human tonsil--derived ex vivo immune data with advanced protein AI models. Using population-scale immune response patterns, we assess and engineer antibody sequences to lower ADA probability ahead of clinical development.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Christian Vahlensieck
Chief Scientific Officer
Lucas Schaus
Chief Technical Officer
Anatol Ehrlich
VP - Bus. Development
Punit Mehra
Browse more venture capital transactions:
Prev: 7/3/2026: Venice AI venture capital transaction
Next: 7/3/2026: PlayBlue Sports venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC investment data records on this site are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs